John H Holcombe

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin
    Matthew C Riddle
    Oregon Health and Sciences University, Portland, OR, USA
    Diabetes Metab Res Rev 22:483-91. 2006
  2. ncbi Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents
    John H Holcombe
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Clin Ther 24:629-38. 2002
  3. ncbi Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy
    James K Malone
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Clin Ther 26:2034-44. 2004
  4. ncbi Prevalence of other diabetes-associated complications and comorbidities and its impact on health care charges among patients with diabetic neuropathy
    Yang Zhao
    Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN 46221, USA
    J Diabetes Complications 24:9-19. 2010
  5. ncbi Comparing clinical and economic characteristics between commercially-insured patients with diabetic neuropathy and demographically-matched diabetic controls
    Yang Zhao
    Eli Lilly and Company, Indianapolis, IN 46221, USA
    Curr Med Res Opin 25:585-97. 2009
  6. ncbi A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus
    Sherwyn Schwartz
    Diabetes and Glandular Disease Research Center, San Antonio, Texas, USA
    Clin Ther 28:1649-57. 2006
  7. ncbi Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
    David C Klonoff
    Diabetes Research Institute, Mills Peninsula Health Services, San Mateo, CA, USA
    Curr Med Res Opin 24:275-86. 2008
  8. ncbi Quantifying the effect of exenatide and insulin glargine on postprandial glucose excursions in patients with type 2 diabetes
    Robert G Brodows
    Curr Med Res Opin 24:1395-7. 2008
  9. ncbi Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study
    Sherwyn L Schwartz
    Diabetes and Glandular Disease Research Center, San Antonio, Texas, USA
    Clin Ther 30:858-67. 2008
  10. ncbi How long should insulin be used once a vial is started?
    Martin M Grajower
    Department of Medicine Endocrinology, Albert Einstein College of Medicine, Riverdale, New York 10463, USA
    Diabetes Care 26:2665-6; discussion 266-9. 2003

Detail Information

Publications12

  1. ncbi Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin
    Matthew C Riddle
    Oregon Health and Sciences University, Portland, OR, USA
    Diabetes Metab Res Rev 22:483-91. 2006
    ..CONCLUSIONS: Exenatide added to maximally effective doses of SU or SU plus MET resulted in a sustained reduction in HbA(1c) and a progressive reduction in weight over 1 1/2 years...
  2. ncbi Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents
    John H Holcombe
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Clin Ther 24:629-38. 2002
    ....
  3. ncbi Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy
    James K Malone
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Clin Ther 26:2034-44. 2004
    ....
  4. ncbi Prevalence of other diabetes-associated complications and comorbidities and its impact on health care charges among patients with diabetic neuropathy
    Yang Zhao
    Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN 46221, USA
    J Diabetes Complications 24:9-19. 2010
    ..Diabetic neuropathy (DN) is a common complication associated with diabetes. This study assesses the prevalence of other diabetes-related complications or comorbidities among DN patients and its marginal contribution to health care charges...
  5. ncbi Comparing clinical and economic characteristics between commercially-insured patients with diabetic neuropathy and demographically-matched diabetic controls
    Yang Zhao
    Eli Lilly and Company, Indianapolis, IN 46221, USA
    Curr Med Res Opin 25:585-97. 2009
    ..To examine medical conditions associated with diabetic neuropathy (DN) and to identify drivers of healthcare charges and utilization using administrative claims...
  6. ncbi A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus
    Sherwyn Schwartz
    Diabetes and Glandular Disease Research Center, San Antonio, Texas, USA
    Clin Ther 28:1649-57. 2006
    ..Furthermore, greater amounts of rapid-acting insulin contained within the mixture were associated with better PPG control...
  7. ncbi Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
    David C Klonoff
    Diabetes Research Institute, Mills Peninsula Health Services, San Mateo, CA, USA
    Curr Med Res Opin 24:275-86. 2008
    ..The objective of this study was to evaluate the effects of > or = 3 years exenatide therapy on glycemic control, body weight, cardiometabolic markers, and safety...
  8. ncbi Quantifying the effect of exenatide and insulin glargine on postprandial glucose excursions in patients with type 2 diabetes
    Robert G Brodows
    Curr Med Res Opin 24:1395-7. 2008
    ....
  9. ncbi Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study
    Sherwyn L Schwartz
    Diabetes and Glandular Disease Research Center, San Antonio, Texas, USA
    Clin Ther 30:858-67. 2008
    ..The aim of this study was to examine the glucose-lowering effect of exenatide over 24 hours in patients with type 2 diabetes with inadequate glycemic control using metformin, with or without a thiazolidinedione (TZD)...
  10. ncbi How long should insulin be used once a vial is started?
    Martin M Grajower
    Department of Medicine Endocrinology, Albert Einstein College of Medicine, Riverdale, New York 10463, USA
    Diabetes Care 26:2665-6; discussion 266-9. 2003
  11. ncbi Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials
    John B Buse
    Division of Endocrinology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
    Clin Ther 29:139-53. 2007
    ..Some patients were followed up in open-label extensions to provide 'real-world' exenatide clinical experience...
  12. ncbi Management of Type 2 diabetes: the role of incretin mimetics
    Anthony H Stonehouse
    Amylin Pharmaceuticals, Inc, 9360 Towne Centre Drive, San Diego, CA 92121, USA
    Expert Opin Pharmacother 7:2095-105. 2006
    ..Agents that manipulate the physiological actions of incretin hormones, such as glucagon-like hormone-1, may significantly benefit patients with Type 2 diabetes...